Hadassah

Hadassah Clinical Trial Reveals Safety and Efficacy of Stem Cell Technology in Treating ALS

Wednesday, Feb 15 2012

"This may represent the biggest hope in the field of degenerative diseases like ALS," Prof. Dimitrios Karussis, head of the Hadassah University Medical Center's Multiple Sclerosis Center, said about the clinical trial just completed at Hadassah where stem cells were used to treat Amyotrophic Lateral Sclerosis (ALS).

Even though this was a trial to determine the safety of the technology, early clinical follow up of the patients demonstrated an improvement in breathing and swallowing ability as well as in muscular power. "I am very excited about the safety results, as well as the indications of efficacy," Prof. Karussis said. The initial patients who were treated with BrainStorm Cell Therapeutics' NurOwn™ stem cell technology experienced no significant side effects in this Phase I/II clinical trial. As a result, Hadassah's ethics and safety committee has now granted BrainStorm approval to proceed with treating additional patients.

NurOwn™ technology processes adult human stem cells that are present in bone marrow and are capable of self-renewal and differentiation into many other cell types. A progressive neurodegenerative disease, ALS, often referred to as Lou Gehrig's disease, affects nerve cells in the brain and the spinal cord. With this technology, the bone marrow cells are induced to differentiate into cells capable of releasing neurotrophic factors which can help ALS patients. According to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year and it is estimated that as many as 30,000 Americans may have the disease at any given time.

The study, led by Prof. Karussis, is being conducted in conjunction with a scientific team from BrainStorm.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More